Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells.

Noh H, Zhao Q, Yan J, Kong LY, Gabrusiewicz K, Hong S, Xia X, Heimberger AB, Li S.

Cancer Lett. 2018 Jul 6;433:176-185. doi: 10.1016/j.canlet.2018.07.008. [Epub ahead of print]

PMID:
29991446
2.

The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.

Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Eric Davis R, Huang S, Fuller GN, Rao A, Heimberger AB, Li S, Rao G.

J Natl Cancer Inst. 2018 Jun 26. doi: 10.1093/jnci/djy107. [Epub ahead of print]

PMID:
29947810
3.

Profiles of Brain Metastases: Prioritization of Therapeutic Targets.

Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB.

Int J Cancer. 2018 Jun 19. doi: 10.1002/ijc.31624. [Epub ahead of print]

PMID:
29923182
4.

Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.

Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, Mehta S, Gatalica Z, Swensen J, Sanai N, Spetzler D, Heimberger AB.

J Neuropathol Exp Neurol. 2018 Jun 1;77(6):437-442. doi: 10.1093/jnen/nly022.

5.

Comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma".

Caruso H, Heimberger AB.

Neuro Oncol. 2018 Jun 18;20(7):1003-1004. doi: 10.1093/neuonc/noy045. No abstract available.

PMID:
29648659
6.

Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes.

Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger AB.

Oncoimmunology. 2018 Jan 16;7(4):e1412909. doi: 10.1080/2162402X.2017.1412909. eCollection 2018.

7.

Identification of metabolites in plasma for predicting survival in glioblastoma.

Shen J, Song R, Hodges TR, Heimberger AB, Zhao H.

Mol Carcinog. 2018 Aug;57(8):1078-1084. doi: 10.1002/mc.22815. Epub 2018 Apr 16.

PMID:
29603794
8.

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.

Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang J, Xiao N, Greil R, Rinnerthaler G, Gampenrieder SP, Heimberger AB, Berry DA, Barker A, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Magee D, Miglarese MR, Famulok M, Mayer G, Spetzler D.

Nat Commun. 2018 Mar 23;9(1):1219. doi: 10.1038/s41467-018-03631-z.

9.

Ependymomas overexpress chemoresistance and DNA repair-related proteins.

Ferguson SD, Zhou S, Xiu J, Hashimoto Y, Sanai N, Kim L, Kesari S, de Groot J, Spetzler D, Heimberger AB.

Oncotarget. 2017 Dec 15;9(8):7822-7831. doi: 10.18632/oncotarget.23288. eCollection 2018 Jan 30.

10.

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Gabriel Sauvé CE, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW.

Cancer Cell. 2018 Jan 8;33(1):152. doi: 10.1016/j.ccell.2017.12.012. No abstract available.

11.

Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma.

Narang S, Kim D, Aithala S, Heimberger AB, Ahmed S, Rao D, Rao G, Rao A.

Oncotarget. 2017 Sep 5;8(60):101244-101254. doi: 10.18632/oncotarget.20643. eCollection 2017 Nov 24.

12.

Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients.

Jacobs DI, Liu Y, Gabrusiewicz K, Tsavachidis S, Armstrong GN, Zhou R, Wei J, Ivan C, Calin G, Molinaro AM, Rice T, Bracci PM, Hansen HM, Wiencke JK, Wrensch MR, Heimberger AB, Bondy ML.

J Neurooncol. 2018 Jan;136(1):33-39. doi: 10.1007/s11060-017-2622-6. Epub 2017 Sep 30.

PMID:
28965162
13.

Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma.

Shen J, Hodges TR, Song R, Gong Y, Calin GA, Heimberger AB, Zhao H.

Mol Carcinog. 2018 Jan;57(1):137-141. doi: 10.1002/mc.22739. Epub 2017 Oct 10.

PMID:
28926136
14.

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CG, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW.

Cancer Cell. 2017 Jul 10;32(1):42-56.e6. doi: 10.1016/j.ccell.2017.06.003. Erratum in: Cancer Cell. 2018 Jan 8;33(1):152.

15.

Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.

Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G.

Lancet Oncol. 2017 Aug;18(8):1040-1048. doi: 10.1016/S1470-2045(17)30414-X. Epub 2017 Jul 4.

PMID:
28687375
16.

Immune Checkpoint Inhibitors for Brain Metastases.

Tan AC, Heimberger AB, Menzies AM, Pavlakis N, Khasraw M.

Curr Oncol Rep. 2017 Jun;19(6):38. doi: 10.1007/s11912-017-0596-3. Review.

PMID:
28417311
17.

Tumor Vaccines for Malignant Gliomas.

Srinivasan VM, Ferguson SD, Lee S, Weathers SP, Kerrigan BCP, Heimberger AB.

Neurotherapeutics. 2017 Apr;14(2):345-357. doi: 10.1007/s13311-017-0522-2. Review.

18.

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.

Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB.

Neuro Oncol. 2017 Aug 1;19(8):1047-1057. doi: 10.1093/neuonc/nox026.

PMID:
28371827
19.

Immune Checkpoint Inhibitors in Gliomas.

Tan AC, Heimberger AB, Khasraw M.

Curr Oncol Rep. 2017 Apr;19(4):23. doi: 10.1007/s11912-017-0586-5. Review.

PMID:
28303490
20.

Serum microRNA profiling in patients with glioblastoma: a survival analysis.

Zhao H, Shen J, Hodges TR, Song R, Fuller GN, Heimberger AB.

Mol Cancer. 2017 Mar 11;16(1):59. doi: 10.1186/s12943-017-0628-5.

21.

Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation.

Shingu T, Ho AL, Yuan L, Zhou X, Dai C, Zheng S, Wang Q, Zhong Y, Chang Q, Horner JW, Liebelt BD, Yao Y, Hu B, Chen Y, Fuller GN, Verhaak RG, Heimberger AB, Hu J.

Nat Genet. 2017 Jan;49(1):75-86. doi: 10.1038/ng.3711. Epub 2016 Nov 14.

22.

The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.

Hu J, Yan J, Rao G, Latha K, Overwijk WW, Heimberger AB, Li S.

Int Rev Immunol. 2016 Jul 3;35(4):325-339. Epub 2014 Sep 26. Review.

23.

Immune modulatory nanoparticle therapeutics for intracerebral glioma.

Yaghi NK, Wei J, Hashimoto Y, Kong LY, Gabrusiewicz K, Nduom EK, Ling X, Huang N, Zhou S, Kerrigan BC, Levine JM, Fajt VR, Levine G, Porter BF, Marcusson EG, Tachikawa K, Chivukula P, Webb DC, Payne JE, Heimberger AB.

Neuro Oncol. 2017 Mar 1;19(3):372-382. doi: 10.1093/neuonc/now198.

24.

Interrogating Metabolism in Brain Cancer.

Salzillo TC, Hu J, Nguyen L, Whiting N, Lee J, Weygand J, Dutta P, Pudakalakatti S, Millward NZ, Gammon ST, Lang FF, Heimberger AB, Bhattacharya PK.

Magn Reson Imaging Clin N Am. 2016 Nov;24(4):687-703. doi: 10.1016/j.mric.2016.07.003. Review.

25.

Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells.

Noh H, Yan J, Hong S, Kong LY, Gabrusiewicz K, Xia X, Heimberger AB, Li S.

Oncotarget. 2016 Nov 1;7(44):72021-72032. doi: 10.18632/oncotarget.12458.

26.

GBM-associated mutations and altered protein expression are more common in young patients.

Ferguson SD, Xiu J, Weathers SP, Zhou S, Kesari S, Weiss SE, Verhaak RG, Hohl RJ, Barger GR, Reddy SK, Heimberger AB.

Oncotarget. 2016 Oct 25;7(43):69466-69478. doi: 10.18632/oncotarget.11617.

27.

Prioritization schema for immunotherapy clinical trials in glioblastoma.

Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB.

Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun. Review.

28.

Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression.

Kong LY, Wei J, Fuller GN, Schrand B, Gabrusiewicz K, Zhou S, Rao G, Calin G, Gilboa E, Heimberger AB.

Oncoimmunology. 2015 Dec 21;5(5):e1117739. doi: 10.1080/2162402X.2015.1117739. eCollection 2016 May.

29.

MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer.

Lin J, Xu K, Wei J, Heimberger AB, Roth JA, Ji L.

J Gene Ther. 2016 Feb;2(1). pii: 6. Epub 2016 Feb 13.

30.

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB.

Neuro Oncol. 2016 Oct;18(10):1357-66. doi: 10.1093/neuonc/now132. Epub 2016 Jul 1.

31.

miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis.

Xue J, Zhou A, Wu Y, Morris SA, Lin K, Amin S, Verhaak R, Fuller G, Xie K, Heimberger AB, Huang S.

Cancer Res. 2016 Jul 15;76(14):4293-304. doi: 10.1158/0008-5472.CAN-15-3073. Epub 2016 May 31.

32.

Immunotherapy in glioblastoma: emerging options in precision medicine.

Hodges TR, Ferguson SD, Heimberger AB.

CNS Oncol. 2016 Jul;5(3):175-86. doi: 10.2217/cns-2016-0009. Epub 2016 May 26. Review.

33.

Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor.

Caruso HG, Torikai H, Zhang L, Maiti S, Dai J, Do KA, Singh H, Huls H, Lee DA, Champlin RE, Heimberger AB, Cooper LJ.

J Immunother. 2016 Jun;39(5):205-17. doi: 10.1097/CJI.0000000000000126.

34.

Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype.

Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy LM, Maiti SN, Thomas G, Zhou S, Wang Q, Elakkad A, Liebelt BD, Yaghi NK, Ezhilarasan R, Huang N, Weinberg JS, Prabhu SS, Rao G, Sawaya R, Langford LA, Bruner JM, Fuller GN, Bar-Or A, Li W, Colen RR, Curran MA, Bhat KP, Antel JP, Cooper LJ, Sulman EP, Heimberger AB.

JCI Insight. 2016;1(2). pii: e85841. Epub 2016 Feb 25.

35.

Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope?

Ferguson SD, Srinivasan VM, Ghali MG, Heimberger AB.

Immunotherapy. 2016;8(4):413-23. doi: 10.2217/imt.16.2. Review.

PMID:
26973123
36.

Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes.

Zhao H, Heimberger AB, Lu Z, Wu X, Hodges TR, Song R, Shen J.

Oncotarget. 2016 Apr 12;7(15):20486-95. doi: 10.18632/oncotarget.7974.

37.

Principles of immunotherapy.

Liebelt BD, Finocchiaro G, Heimberger AB.

Handb Clin Neurol. 2016;134:163-81. doi: 10.1016/B978-0-12-802997-8.00010-4. Review.

PMID:
26948354
38.

MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.

Wei J, Nduom EK, Kong LY, Hashimoto Y, Xu S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, Ivan C, Fuller GN, Gilbert MR, Overwijk W, Calin GA, Heimberger AB.

Neuro Oncol. 2016 May;18(5):639-48. doi: 10.1093/neuonc/nov292. Epub 2015 Dec 11.

39.

Immunosuppressive mechanisms in glioblastoma.

Nduom EK, Weller M, Heimberger AB.

Neuro Oncol. 2015 Nov;17 Suppl 7:vii9-vii14. doi: 10.1093/neuonc/nov151. Review.

40.

Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Lee DA, Heimberger AB, Champlin RE, Cooper LJ.

Cancer Res. 2015 Sep 1;75(17):3505-18. doi: 10.1158/0008-5472.CAN-15-0139.

41.

PD-L1 expression and prognostic impact in glioblastoma.

Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB.

Neuro Oncol. 2016 Feb;18(2):195-205. doi: 10.1093/neuonc/nov172. Epub 2015 Aug 30.

42.

FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.

Yan J, Kong LY, Hu J, Gabrusiewicz K, Dibra D, Xia X, Heimberger AB, Li S.

J Natl Cancer Inst. 2015 May 13;107(8). pii: djv137. doi: 10.1093/jnci/djv137. Print 2015 Aug.

43.

FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells.

Gong AH, Wei P, Zhang S, Yao J, Yuan Y, Zhou AD, Lang FF, Heimberger AB, Rao G, Huang S.

Cancer Res. 2015 Jun 1;75(11):2337-48. doi: 10.1158/0008-5472.CAN-14-2800. Epub 2015 Apr 1.

44.

The role of STAT3 in tumor-mediated immune suppression.

Ferguson SD, Srinivasan VM, Heimberger AB.

J Neurooncol. 2015 Jul;123(3):385-94. doi: 10.1007/s11060-015-1731-3. Epub 2015 Feb 22. Review.

PMID:
25700834
45.

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH.

Neuro Oncol. 2015 Jun;17(6):854-61. doi: 10.1093/neuonc/nou348. Epub 2015 Jan 13.

46.

Therapeutic targets in subependymoma.

Kong LY, Wei J, Haider AS, Liebelt BD, Ling X, Conrad CA, Fuller GN, Levine NB, Priebe W, Sawaya R, Heimberger AB.

J Neuroimmunol. 2014 Dec 15;277(1-2):168-75. doi: 10.1016/j.jneuroim.2014.10.008. Epub 2014 Oct 31.

PMID:
25465288
47.

Immunotherapy for primary brain tumors: no longer a matter of privilege.

Fecci PE, Heimberger AB, Sampson JH.

Clin Cancer Res. 2014 Nov 15;20(22):5620-9. doi: 10.1158/1078-0432.CCR-14-0832. Review.

48.

Epidermal growth factor receptor and variant III targeted immunotherapy.

Congdon KL, Gedeon PC, Suryadevara CM, Caruso HG, Cooper LJ, Heimberger AB, Sampson JH.

Neuro Oncol. 2014 Oct;16 Suppl 8:viii20-5. doi: 10.1093/neuonc/nou236. Review.

49.

Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis.

Gressot LV, Doucette TA, Yang Y, Fuller GN, Heimberger AB, Bögler O, Rao A, Latha K, Rao G.

Int J Cancer. 2015 May 1;136(9):2047-54. doi: 10.1002/ijc.29264. Epub 2014 Oct 23.

50.

Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma.

Xu S, Wei J, Wang F, Kong LY, Ling XY, Nduom E, Gabrusiewicz K, Doucette T, Yang Y, Yaghi NK, Fajt V, Levine JM, Qiao W, Li XG, Lang FF, Rao G, Fuller GN, Calin GA, Heimberger AB.

J Natl Cancer Inst. 2014 Jun 28;106(8). pii: dju162. doi: 10.1093/jnci/dju162. Print 2014 Aug.

Supplemental Content

Loading ...
Support Center